Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

NCT ID: NCT03099161

Last Updated: 2019-06-05

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-06-27
• Study Completion Date: 2018-02-21

Brief Summary

The purpose of this study is to evaluate the safety and preliminary efficacy of preladenant (MK-3814A) alone and in combination with pembrolizumab (MK-3475) (pembro) in participants with advanced solid tumors that have not responded to prior therapy. This study will be done in 2 parts. Part 1 will identify and confirm the recommended Phase 2 dose (RP2D) of preladenant when given alone or in combination with pembrolizumab. Part 2 of the study will determine the safety and efficacy of preladenant in combination with pembrolizumab at the RP2D in participants with select solid tumors .

Conditions

Neoplasm

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Preladenant 25 mg Twice a Day (BID)

During an initial dose evaluation phase, participants received 25 mg of preladenant orally twice a day (BID) on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was to be established based on the number of dose limiting toxicities (DLTs) at each dose level administered. Participants continued receiving 25 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.

Group Type: EXPERIMENTAL

preladenant

Intervention Type: DRUG

Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle

Preladenant 50 mg BID

During an initial dose evaluation phase, participants received 50 mg of preladenant orally BID on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was established based on the number of DLTs at each dose level administered. Participants continued receiving 50 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.

Group Type: EXPERIMENTAL

preladenant

Intervention Type: DRUG

Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle

Preladenant + Pembrolizumab

During an initial dose evaluation phase, participants received 25 mg of preladenant administered orally BID on Days 1 through 21 in combination with 200 mg pembrolizumab administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (for a maximum of 35 cycles). Participants continued receiving preladenant 25 mg BID in combination with 200 mg pembrolizumab for each infusion cycle until discontinuation or receiving a maximum of 35 cycles.

Group Type: EXPERIMENTAL

preladenant

Intervention Type: DRUG

Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle

pembrolizumab

Intervention Type: BIOLOGICAL

Administered as IV infusion on Day 1 of each 21-day cycle

Interventions

preladenant

Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle

Intervention Type: DRUG

pembrolizumab

Administered as IV infusion on Day 1 of each 21-day cycle

Intervention Type: BIOLOGICAL

Other Intervention Names

MK-3814A; KEYTRUDA®; MK-3475

Eligibility Criteria

Inclusion Criteria

• Has a histologically- or pathologically-documented, locally-advanced or metastatic solid tumor for which standard therapy, either does not exist or has been proven ineffective, intolerable or refused by the participant. Each participant must have received at least one and up to five prior lines of cancer treatment regimens, excluding neo-adjuvant, adjuvant, maintenance treatment and surgery
• Has provided a tumor tissue sample (archival or newly obtained core or excisional biopsy of a tumor lesion)
• Has measurable disease per RECIST 1.1
• Has an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Females must not be pregnant
• Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study therapy, throughout the study period, and for up to 120 days after the last dose of study therapy

Exclusion Criteria

• Has disease that is suitable for local treatment administered with curative intent
• Has received previous treatment with an immunomodulatory agent (e.g, anti- Programmed Cell Death Receptor 1/ Programmed Cell Death Receptor Ligand 1 or anti-cytotoxic T-lymphocyte-associated antigen-4) and was discontinued from treatment due to a Grade 3 or higher immune-related adverse event
• Has received previous treatment with an adenosine A2a receptor antagonist (e.g. CPI-444, HTL1071, PBF-509)
• Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks of the first dose of study therapy, or has not recovered to Common Toxicity Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse event
• Is currently participating or has participated in a study with an investigational agent or using an investigational device within 28 days of the first dose of study therapy
• Is currently taking or has taken drugs that interfere with Cytochrome P450 (CYP)3A4 or CYP2C8 or grapefruit and star fruit in diet within 14 days of the first dose of study therapy
• Is currently taking or has taken proton pump inhibitors within 5 days of the first dose of study therapy
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days of the first dose of study therapy
• Is expected to require any other form of systemic or localized antineoplastic therapy while on study
• Has a history of a second malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years
• Has clinically active central nervous system metastases and/or carcinomatous meningitis
• History of a severe hypersensitivity reaction to treatment with the monoclonal antibody/components of the study drug
• Has an active infection requiring therapy
• History of interstitial lung disease
• History of (non-infectious) pneumonitis that required steroids or current pneumonitis
• History of active tuberculosis
• Has an active autoimmune disease that has required systemic treatment in the past 2 years
• Has received a live-virus vaccine within 30 days of the first dose of study therapy
• Has known Human Immunodeficiency Virus (HIV) (HIV 1 or 2 antibodies) and/or known active and acute Hepatitis B or C infections
• Has known psychiatric or substance abuse disorders that would interfere with the ability to cooperate with the requirements of the study
• Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
• Has not fully recovered from any effects of major surgery without significant detectable infection
• Has had surgery that required general anesthesia within 2 weeks of the first dose of study therapy
• Has had surgery that required regional/epidural anesthesia within 72 hours of the first dose of study therapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

START Midwest ( Site 0001)

Grand Rapids, Michigan, United States

Princess Margaret Hospital ( Site 0010)

Toronto, Ontario, Canada

Jewish General Hospital ( Site 0011)

Montreal, Quebec, Canada

Rambam Health Care Campus ( Site 0020)

Haifa, , Israel

Tel Aviv Sourasky Medical Center ( Site 0021)

Tel Aviv, , Israel

Countries

United States; Canada; Israel

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

MK-3814A-062

Identifier Type: OTHER

Identifier Source: secondary_id

3814A-062

Identifier Type: -

Identifier Source: org_study_id